Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1021

Sort by

Sort Order Select

Journal Articles

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies

Deborah M. Stephens, John C. Byrd

Blood (2021) 138 (13): 1099–1109.

https://doi.org/10.1182/blood.2020006783

Published: 2021

Journal Articles

Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88

Blood (2021) 137 (18): 2495–2508.

https://doi.org/10.1182/blood.2020008414

Published: 2021

Includes: Supplemental data

Journal Articles

Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027–2037.

Blood (2021) 137 (8): 1131.

https://doi.org/10.1182/blood.2021010665

Published: 2021

Journal Articles

Identification of 2 DNA methylation subtypes of Waldenström macroglobulinemia with plasma and memory B-cell features

Damien Roos-Weil, Brian Giacopelli, Marine Armand, Véronique Della-Valle, Hussein Ghamlouch, Camille Decaudin, Marlen Metzner, Junyan Lu, Magali Le Garff-Tavernier, Véronique Leblond, Paresh Vyas, Thorsten Zenz, Florence Nguyen-Khac, Olivier A. Bernard, Christopher C. Oakes

Blood (2020) 136 (5): 585–595.

https://doi.org/10.1182/blood.2020005081

Published: 2020

Includes: Supplemental data

Journal Articles

Epigenomics in Waldenström macroglobulinemia

Zachary R. Hunter, Steven P. Treon

Blood (2020) 136 (5): 527–529.

https://doi.org/10.1182/blood.2020006244

Published: 2020

Journal Articles

How I treat Waldenström macroglobulinemia

Meletios A. Dimopoulos, Efstathios Kastritis

Blood (2019) 134 (23): 2022–2035.

https://doi.org/10.1182/blood.2019000725

Published: 2019

Journal Articles

Platelet RNA Splicing Profiles Can Distinguish IgM MGUS Patients from Healthy Individuals

Mick J.M. Van Eijs, MSc, Nicolette C. Notermans, MD PhD, Tom Würdinger, PhD, Monique C. Minnema, MD PhD

Blood (2019) 134 (Supplement_1): 3771.

https://doi.org/10.1182/blood-2019-124325

Published: 2019

Journal Articles

MLL1 Modulates IgM and Inflammatory Cytokines in Waldenstrom's Macroglobulinemia

Mona Karbalivand, MSc, BSc, Weiguo Han, PhD, Luciana L Almada, PhD, Stephen M Ansell, MD PhD, Martin Fernandez-Zapico, MD, Sherine F Elsawa, PhD

Blood (2019) 134 (Supplement_1): 3966.

https://doi.org/10.1182/blood-2019-125833

Published: 2019

Journal Articles

Preliminary Results from a Phase I Study of SHC014748M in Patients with Relapsed or Refractory Indolent B-Cell Lymphomas

Wei Xu, MD PhD, Jie Jin, MD PhD, Keshu Zhou, MD, Li Wang, MD, Huayuan Zhu, Jiejing Qian, Jianying Huang, Fuling Zhou, MD, Xiaohong Xu, Zhiqiang Wang, Wei Guo, Jianyong Li, MD

Blood (2019) 134 (Supplement_1): 4000.

https://doi.org/10.1182/blood-2019-126707

Published: 2019

Journal Articles

Coexistence of B-Cell Dyscrasia with Large Granular Lymphocytic Leukemia

Hassan Awada, Jibran Durrani, Ashwin Kishtagari, MBBS, Valeria Visconte, PhD, Reda Z. Mahfouz, MD PhD

Blood (2019) 134 (Supplement_1): 3750.

https://doi.org/10.1182/blood-2019-132220

Published: 2019

Journal Articles

Randomized Comparison of Rituximab Versus Bortezomib Plus Cyclophosphamide and Dexamethasone in Newly Diagnosed Waldenstrom Macroglobulinemia Patients

Shuhua Yi, MD, Wenjie Xiong, Yi Wang, Rui Lv, Li Zengjun, Wei Liu, Tingyu Wang, An Gang, MD, Shuhui Deng, MD, Yan Xu, MD, Weiwei Sui, Dehui Zou, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 4003.

https://doi.org/10.1182/blood-2019-130133

Published: 2019

Journal Articles

Glutathione Metabolism Contributes to the Pathobiology of Waldenstrom's Macroglobulinemia

Shahrzad Jalali, PhD, Jie Shi, MD PhD, Hyojin Kim, PhD, Zhi-Zhang Yang, MD, Stephen M Ansell, MD

Blood (2019) 134 (Supplement_1): 3971.

https://doi.org/10.1182/blood-2019-124558

Published: 2019

Journal Articles

Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia

Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Sven de Vos, MD PhD, Gilles A. Salles, MD PhD, Wojciech Jurczak, MD PhD, Nishan Rajakumaraswamy, MD, Guan Xing, PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 4006.

https://doi.org/10.1182/blood-2019-121936

Published: 2019

Journal Articles

Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Krish Patel, MD, Jean-Marie Michot, MD, Asher A. Chanan-Khan, MD, Gilles A. Salles, MD PhD, Guillaume Cartron, MD PhD, Frederic Peyrade, MD, Reda Bouabdallah, Erin G. Reid, MD MS, Sheeba K. Thomas, MD, William G. Wierda, MD PhD, David Liebowitz, MD, John M. Pagel, MD PhD DSc, Vincent Ribrag, MD, M. Wayne Saville, MD, Chelsea M. Johnson, BSN, Thomas Ly, PhD, Tycel J. Phillips, MD

Blood (2019) 134 (Supplement_1): 4079.

https://doi.org/10.1182/blood-2019-128564

Published: 2019

Journal Articles

IgM-Gammopathies Transformed into Aggressive Lymphoma: Incidence, Basal Clinical Features and Outcome of a Registry Based, Spanish Retrospective Series

Irene Dogliotti, MD, Cristina Jiménez, PhD, Federica Cavallo, MD PhD, Noemi Puig, MD PhD, Gian Maria Zaccaria, PhD, Veronica Gonzalez De La Calle, MD PhD, Maria Eugenia Sarasquete, PhD, Miguel Alcoceba, Pilar Delgado, MD, Maria Rosa López, MD, Aránzazu García Mateo, PhD, Simone Ferrero, MD, Mario Boccadoro, Marcos González, Ramón García-Sanz, MD PhD

Blood (2019) 134 (Supplement_1): 4011.

https://doi.org/10.1182/blood-2019-123353

Published: 2019

Journal Articles

An Analysis from the WM UK Rory Morrison Registry: Waldenström's Macroglobulinaemia Patient Demographics, Disease Characteristics and Evolving Treatment Choices

Oliver Tomkins, BMBS, MRCP, Joshua Bomsztyk, Helen McCarthy, MBBS, PhD, Jaimal Kothari, Dima El-Sharkawi, Charalampia Kyriakou, Guy Pratt, Ali Rismani, MBBS, Shirley D'Sa

Blood (2019) 134 (Supplement_1): 4016.

https://doi.org/10.1182/blood-2019-129212

Published: 2019

Journal Articles

A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Max S. Topp, MD, Johannes Duell, MD, Jingjin Li, PhD, Vladimir Jankovic, MD, Israel Lowy, MD PhD, David Sternberg, MD PhD, Lieve Adriaens, PharmD, Mary Peterman, PharmD, Srikanth R. Ambati, MBBS, MD, Rajat Bannerji, MD PhD

Blood (2019) 134 (Supplement_1): 4007.

https://doi.org/10.1182/blood-2019-126670

Published: 2019

Journal Articles

A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma

David A. Bond, MD, Vedat Yildiz, Lai Wei, PhD, Lapo Alinari, MD PhD, Basem M. William, MRCP,MD, Jonathan E. Brammer, MD, Beth A. Christian, MD, Kristie A. Blum, MD, Kami J. Maddocks, MD

Blood (2019) 134 (Supplement_1): 4091.

https://doi.org/10.1182/blood-2019-130539

Published: 2019

Journal Articles

Prognostic Value of Disease Risk Score Versus Gait Speed in Older Adults with Lymphoma

Lee Mozessohn, MD, Liying Zhang, PhD, Oreofe O. Odejide, MD MPH, Anna M. Tanasijevic, MPH, Richard Chen, BA, Rena Buckstein, MD FRCPC, Robert J. Soiffer, MD, Jorge J Castillo, MD, Andrew Keezer, BS, Jane Driver, MD MPH, Gregory A. Abel, MDMPH

Blood (2019) 134 (Supplement_1): 68.

https://doi.org/10.1182/blood-2019-124946

Published: 2019

Journal Articles

Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response at 1 Year in Light Chain (AL) Amyloidosis

Sneha Purvey, MD, Kenneth Seier, MS, Sean M. Devlin, PhD, Josel D Ruiz, MPH, Molly A. Maloy, MS, Gunjan L. Shah, MDMS, Hani Hassoun, MD, Sergio A. Giralt, MD, Heather J Landau, MD

Blood (2019) 134 (Supplement_1): 4577.

https://doi.org/10.1182/blood-2019-129195

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies

Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88

Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027–2037.

Identification of 2 DNA methylation subtypes of Waldenström macroglobulinemia with plasma and memory B-cell features

Epigenomics in Waldenström macroglobulinemia

How I treat Waldenström macroglobulinemia

Platelet RNA Splicing Profiles Can Distinguish IgM MGUS Patients from Healthy Individuals

MLL1 Modulates IgM and Inflammatory Cytokines in Waldenstrom's Macroglobulinemia

Preliminary Results from a Phase I Study of SHC014748M in Patients with Relapsed or Refractory Indolent B-Cell Lymphomas

Coexistence of B-Cell Dyscrasia with Large Granular Lymphocytic Leukemia

Randomized Comparison of Rituximab Versus Bortezomib Plus Cyclophosphamide and Dexamethasone in Newly Diagnosed Waldenstrom Macroglobulinemia Patients

Glutathione Metabolism Contributes to the Pathobiology of Waldenstrom's Macroglobulinemia

Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia

Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

IgM-Gammopathies Transformed into Aggressive Lymphoma: Incidence, Basal Clinical Features and Outcome of a Registry Based, Spanish Retrospective Series

An Analysis from the WM UK Rory Morrison Registry: Waldenström's Macroglobulinaemia Patient Demographics, Disease Characteristics and Evolving Treatment Choices

A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma

Prognostic Value of Disease Risk Score Versus Gait Speed in Older Adults with Lymphoma

Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response at 1 Year in Light Chain (AL) Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only